This Article Figures Only Full Text Full Text (PDF) Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Bomanji, J B Articles by Ell, P J Search for Related Content PubMed PubMed Citation Articles by Bomanji, J B Articles by Ell, P J

Functional imaging as an aid to decision-making in metastatic paraganglioma

¹ The Institute of Nuclear Medicine
² Meyerstein Institute of Oncology, The Middlesex Hospital, Mortimer Street, London W1N 8AA, UK

Malignant paraganglioma is a rare and slow growing tumour of neuroendocrine origin. At the time of diagnosis, the tumour is usually widespread, with limited therapeutic options. A variety of functional imaging studies are available for staging the disease, guiding therapy and monitoring treatment response. These include ¹²³I-MIBG or ¹³¹I-MIBG, ¹¹¹In-pentetreotide or ¹¹¹In-lanreotide (somatostatin analogues), and ¹⁸F-FDG positron emission tomography. Various radionuclides, including ¹³¹I and ⁹⁰Y, can be targeted to the tumour using MIBG or pentetreotide. Such targeted radionuclide therapy may provide valuable long-term palliation in such patients. We present two cases with metastatic paragangliomas who had widespread soft tissue and bone metastases. One patient was treatment naive and the second had received previous chemotherapy. The functional imaging work-up performed and the targeted radionuclide therapies considered in these patients are described. Both patients were treated with ¹³¹I-MIBG. Partial tumour response and complete symptomatic and hormonal response was achieved in one patient; in the second patient there was no change.